Ascendis Pharma is a biotechnology company applying its innovative prodrug technology to build a leading, fully integrated rare disease company. Our science-driven and passionate people are advancing a pipeline of endocrinology programs focused on making a difference in patients lives. By utilizing our TransCon technology with clinically validated parent drugs, we create new therapies with potential for best-in-class efficacy, safety and/or convenience.
Ascendis Pharma is headquartered in Copenhagen, Denmark, maintains an office in Palo Alto, California, and has research and development facilities in Heidelberg, Germany, and Copenhagen, Denmark.